Citations

Clear

2438 citation(s) found for "Ly, Amy".

Tissue Ablation: Applications and Perspectives (Adv. Mater. 32/2024)
Çevik, Enes , Demirlenk, Yusuf Mert , Atar, Dila , Saini, Gia , Sheth, Rahul A. , Keum, Hyeongseop , Kim, Jinjoo , Deipolyi, Amy R. , Öklü, Rahmi

Mayo Clinic

Advanced Materials | August 8, 2024 | Volume: 36 | Issue: 32 | Pages: No page available

10.1002/adma.202470259 Get It

Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Hoff, Fieke W. , Blum, William , Huang, Ying , Welkie, Rina Li , Swords, Ronan , Traer, Elie , Stein, Eytan M. , Lin, Tara L. , Patel, Prapti A. , Collins, Robert H. , Baer, Maria R. , Arellano, Martha , Odenike, Olatoyosi , Redner, Robert L. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Foran, James M. , Schiller, Gary J. , Curran, Emily , Koenig, Kristin L , Heerema, Nyla A. , Chen, Timothy L. , Martycz, Molly , Stefanos, Mona , Marcus, Sonja G., Rosenberg, Leonard, Burd, Amy , Yocum, Ashley O. , Borate, Uma , Byrd, John C. , Madanat, Yazan F. , Huang, Ying , Byrd, John C. , Duong, Vu H , Deininger, Michael , Zeidner, Joshua F , Smith, Catherine C , Koenig, Kristin L , Druker, Brian J , Mims, Alice S , Madanat, Yazan , Traer, Elie , Lin, Tara L , Byrd, John C , Archer, Kellie J. , Duong, Vu H. , Stock, Wendy , Zeidner, Joshua F. , Smith, Catherine C. , Marcus, Sonja G., Levine, Ross L.

Mayo Clinic

Blood Advances | August 7, 2024 | Volume: 8 | Issue: 20 | Pages: 5297-5305

10.1182/bloodadvances.2024013685 | PMID 39110987 Get It

Abstract Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ≥60 years treated with lower-intensity treatment (LIT). We aimed to test the prognostic impact of ELN risk in patients with newly diagnosed (ND) AML aged ≥60 years given LIT and to further refine risk stratification for these patients. A total of 595 patients were included: 11% had favorable-, 11% intermediate-, and 78% had adverse-risk AML. ELN risk was prognostic for overall survival (OS) (P < .001) but did not stratify favorable- from intermediate-risk (P = .71). Within adverse-risk AML, the impact of additional molecular abnormalities was further evaluated. Multivariable analysis was performed on a training set (n = 316) and identified IDH2 mutation as an independent favorable prognostic factor, and KRAS, MLL2, and TP53 mutations as unfavorable (P < .05). A “mutation score” was calculated for each combination of these mutations, assigning adverse-risk patients to 2 risk groups: −1 to 0 points (“Beat-AML intermediate”) vs 1+ points (“Beat-AML adverse”). In the final refined risk classification, ELN favorable- and intermediate-risk were combined into a newly defined “Beat-AML favorable-risk” group, in addition to mutation scoring within the ELN adverse-risk group. This approach redefines risk for older patients with ND AML and proposes refined Beat-AML risk groups with improved discrimination for OS (2-year OS, 48% vs 33% vs 11%, respectively; P < .001), providing patients and providers additional information for treatment decision-making.
Evaluating cell type deconvolution in FFPE breast tissue: application to benign breast disease
Liu, Yuanhang , Bhagwate, Aditya , Jons, William , McCauley, Bryan M. , Stephens, Melissa, Littlepage, Laurie E. , Cunningham, Julie M. , Jons, William A, Stallings-Mann, Melody L, Radisky, Derek C. , Cunningham, Julie M , Wang, Chen , Vierkant, Robert A. , Stallings‐Mann, Melody , Carter, Jodi M. , Pfrender, Michael E. , Degnim, Amy C. , Winham, Stacey J. , Wang, Chen

Mayo Clinic

NAR Genomics and Bioinformatics | August 7, 2024 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/nargab/lqae098 | PMID 40162103 Get It

Abstract Transcriptome profiling using RNA sequencing (RNA-seq) of bulk formalin-fixed paraffin-embedded (FFPE) tissue blocks is a standard method in biomedical research. However, when used on tissues with diverse cell type compositions, it yields averaged gene expression profiles, complicating biomarker identification due to variations in cell proportions. To address the need for optimized strategies for defining individual cell type compositions from bulk FFPE samples, we constructed single-cell RNA-seq reference data for breast tissue and tested cell type deconvolution methods. Initial simulation experiments showed similar performances across multiple commonly used deconvolution methods. However, the introduction of FFPE artifacts significantly impacted their performances, with a root mean squared error (RMSE) ranging between 0.04 and 0.17. Scaden, a deep learning-based method, consistently outperformed the others, demonstrating robustness against FFPE artifacts. Testing these methods on our 62-sample RNA-seq benign breast disease cohort in which cell type composition was estimated using digital pathology approaches, we found that pre-filtering of the reference data enhanced the accuracy of most methods, realizing up to a 32% reduction in RMSE. To support further research efforts in this domain, we introduce SCdeconR, an R package designed for streamlined cell type deconvolution assessments and downstream analyses.
Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder
Abbatemarco, JR, Aboseif, Albert , Swetlik, Carol , Widmar, Julie, Harvey, Teresa, Kunchok, Amy , O’Mahony, Julia , Miller, DM, Conway, DS, Miller, Deborah , Miller, D M , Conway, D S , Pittock, Sean J , Aboseif, Albert , Abbatemarco, JR, Harvey, T, Conway, Devon

Mayo Clinic

Multiple Sclerosis Journal | August 6, 2024 | Volume: 30 | Issue: 10 | Pages: 1322-1330

10.1177/13524585241267231 | PMID 39105475 Get It

Background: Little is known about the relationship between neighborhood disadvantage and neuromyelitis optica spectrum disorder (NMOSD) outcomes. Objective: The objective is to determine the impact of neighborhood disadvantage on time from symptom onset to diagnosis and annualized relapse rate (ARR). Methods: Neighborhood disadvantage were captured with the Area Deprivation Index (ADI), a validated measure of neighborhood-level disadvantage. Negative binomial regression models assessed the impact of ADI on diagnostic delay (⩾3 months between symptom onset and diagnosis) and ARR. Results: A total of 158 NMOSD patients were identified, a majority of whom were White (56.3%) and female (89.9%) with a mean age of 46 years at diagnosis. The ADI did not significantly affect odds of diagnostic delay (odds ratio (OR) = 0.99, p = 0.26). In univariable models, the ADI was not significantly associated with ARR (OR = 1.004, p = 0.29), but non-White race (OR = 1.541, p = 0.02) and time on immunosuppressive therapies (ISTs; OR = 0.994, p = 0.03) were. White patients used IST for an average of 81% of the follow-up period, compared to an average of 65% for non-White patients ( p < 0.01). Conclusion: No significant relationship between neighborhood-level disadvantage and diagnostic delay or ARR in NMOSD patients was observed. Non-White patients had a higher ARR, which may be related to less IST use.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Aldoss, Ibrahim , Roloff, Gregory W. , Kopmar, Noam E. , Lin, Chenyu , Advani, Anjali S. , Dekker, Simone E. , O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Katharine, Sutherland, Katherine C. , Ahmed, Mohamed , Zambrano, Héctor, Bradshaw, Danielle , Schwartz, Marc S. , Tracy, Sean , Kubiak, Michal Jakub , Mukherjee, Akash , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Ladha, Abdullah , Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , O’Dwyer, Kristen M. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian , Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Bishop, Michael R. , Pullarkat, Vinod , Muffly, Lori , Lin, Chenyu , Advani, Anjali S , Jeyakumar, Nikeshan , Dykes, Kaitlyn C , Chen, Evan , Bradshaw, Danielle , Dholaria, Bhagirathbhai R , Majhail, Navneet S , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Moore, Jozal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Lee, Catherine J , Leonard, Jessica T , Frey, Noelle V , Luskin, Marlise R , Muffly, Lori , Bachanova, Veronika , Aldoss, Ibrahim , Muhsen, Ibrahim N , Sutherland, Katherine , Roloff, Gregory W , Faramand, Rawan , Gupta, Vishal , Dykes, Kaitlyn C. , Mercadal, Santiago , Schwartz, Marc, Dholaria, Bhagirathbhai , Majhail, Navneet S. , Battiwalla, Minoo , Mathews, John, Hilal, Talal , O'Dwyer, Kristin , Tsai, Stephanie B., Kota, Vamsi , Oliai, Caspian H , Frey, Noelle V. , Bishop, Michael Russell , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal

Mayo Clinic

Blood Advances | August 2, 2024 | Volume: 8 | Issue: 23 | Pages: 6139-6147

10.1182/bloodadvances.2024013747 | PMID 39093952 Get It

Abstract The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patients with relapsed/refractory ALL treated with brexu-cel. Over half of the patients received InO before brexu-cel (InO exposed). InO-exposed patients were more heavily pretreated (P = .02) and frequently had active marrow disease before apheresis (P = .03). Response rate and toxicity profile after brexu-cel were comparable for InO-exposed and InO-naïve patients; however, consolidation therapy after brexu-cel response was used at a higher rate in InO-naïve patients (P = .005). With a median follow-up of 11.4 months, InO-exposed patients had inferior progression-free survival (PFS; P = .013) and overall survival (OS; P = .006) in univariate analyses; however, prior InO exposure did not influence PFS (hazard ratio, 1.20; 95% confidence interval, 0.71-2.03) in multivariate models. Within InO-exposed patients, InO responders had superior PFS (P = .002) and OS (P &lt; .0001) relative to InO-refractory patients. The timing of administering InO did not affect brexu-cel outcomes, with comparable PFS (P = .51) and OS (P = .86) for patients receiving InO as bridging therapy or before apheresis. In conclusion, although InO exposure was associated with inferior survival outcomes after brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively affects brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
Gender Differences in Autonomy Granted to Residents and Fellows During Procedural Training: A Systematic Review and Meta-Analysis
Lund, Sarah , Griffeth, Elaine M. , Williamson, Andrea J.H. , Collings, Amelia T. , Gudmundsdottir, Hallbera , Han, Amy , Kearse, LaDonna , Kratzke, Ian M. , Wilkins, Parvathi , Prokop, Larry J. , Cook, David A. , Williamson, Andrea , Collings, Amelia , Prokop, Larry , Kearse, LaDonna E , Gudmundsdottir, Hallbera

Mayo Clinic

Academic Medicine | August 2, 2024 | Volume: 99 | Issue: 8 | Pages: 922-930

10.1097/acm.0000000000005673 | PMID 38412483 Get It

Abstract Purpose Supervisors may be prone to implicit (unintentional) bias when granting procedural autonomy to trainees due to the subjectivity of autonomy decisions. The authors aimed to conduct a systematic review and meta-analysis to assess the differences in perceptions of procedural autonomy granted to physician trainees based on gender and/or race. Method MEDLINE, Embase, CENTRAL, Scopus, and Web of Science were searched (search date: January 5, 2022) for studies reporting quantitative gender- or race-based differences in perceptions of procedural autonomy of physician trainees. Reviewers worked in duplicate for article selection and data abstraction. Primary measures of interest were self-reported and observer-rated procedural autonomy. Meta-analysis pooled differences in perceptions of procedural autonomy based on trainee gender. Results The search returned 2,714 articles, of which 16 were eligible for inclusion. These reported data for 6,109 trainees (median, 90 per study) and 2,763 supervisors (median, 54 per study). No studies investigated differences in perceptions of autonomy based on race. In meta-analysis of disparities between genders in autonomy ratings (positive number favoring female trainees), pooled standardized mean differences were −0.12 (95% confidence interval [CI], −0.19 to −0.04; P = .003; n = 10 studies) for trainee self-rated autonomy and −0.05 (95% CI, −0.11 to 0.01; P = .07; n = 9 studies) for supervisor ratings of autonomy. Conclusions Limited evidence suggests that female trainees perceived that they received less procedural autonomy than did males. Further research exploring the degree of gender- and race-based differences in procedural autonomy, and factors that influence these differences is warranted.
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Sundby, R. Taylor , Szymanski, Jeffrey J. , Pan, Alexander , Jones, Paul A. , Mahmood, Sana , Reid, Olivia H. , Srihari, Divya , Armstrong, Amy E. , Chamberlain, Stacey , Burgic, Sanita , Weekley, Kara , Murray, Béga , Patel, S. G. , Qaium, Faridi , Lucas, Andrea N. , Fagan, Margaret , Dufek, Anne , Meyer, Christian F. , Collins, Natalie B. , Pratilas, Christine A. , Gross, Andrea M. , Widemann, Brigitte C. , Chaudhuri, Aadel A. , Pan, Alexander C , Mahmood, Sana Z , Patel, Sneh , Dombi, Eva , Gross, Andrea M , Kim, AeRang , Chrisinger, John S A , Dehner, Carina A , Widemann, Brigitte C , Hirbe, Angela C , Chaudhuri, Aadel A , Shern, Jack F , Sundby, R. Taylor , Collins, Natalie B , Dombi, Eva , Kim, AeRang , Chrisinger, John S.A. , Dehner, Carina , Hirbe, Angela C. , Shern, Jack F.

Mayo Clinic

Clinical Cancer Research | August 2, 2024 | Volume: 30 | Issue: 19 | Pages: 4363-4376

10.1158/1078-0432.ccr-24-0797 | PMID 39093127 Get It

Abstract Purpose: Early detection of neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we describe a cell-free DNA (cfDNA) fragmentomic approach that distinguishes nonmalignant, premalignant, and malignant forms of PNST in the cancer predisposition syndrome, NF1. Experimental Design: cfDNA was isolated from plasma samples of a novel cohort of 101 patients with NF1 and 21 healthy controls and underwent whole-genome sequencing. We investigated diagnosis-specific signatures of copy-number alterations with in silico size selection as well as fragment profiles. Fragmentomics were analyzed using complementary feature types: bin-wise fragment size ratios, end motifs, and fragment non-negative matrix factorization signatures. Results: The novel cohort of patients with NF1 validated that our previous cfDNA copy-number alteration–based approach identifies malignant PNST (MPNST) but cannot distinguish between benign and premalignant states. Fragmentomic methods were able to differentiate premalignant states including atypical neurofibromas (AN). Fragmentomics also adjudicated AN cases suspicious for MPNST, correctly diagnosing samples noninvasively, which could have informed clinical management. Conclusions: Novel cfDNA fragmentomic signatures distinguish AN from benign plexiform neurofibromas and MPNST, enabling more precise clinical diagnosis and management. This study pioneers the early detection of malignant and premalignant PNST in NF1 and provides a blueprint for decentralizing noninvasive cancer surveillance in hereditary cancer predisposition syndromes.
Current laboratory testing practices for mismatch repair deficiency and microsatellite instability testing: A survey-based review of current laboratory practices
Austin, Amy, Broaddus, Russell R. , Souers, Rhona J., Kane, Megan E , Kolhe, Ravindra , Miller, Dylan V. , Moncur, Joel T., Ramkissoon, Shakti, Trembath, Dimitri G. , Kolhe, Ravindra , Ramkissoon, Shakti, Tafe, Laura J. , Graham, Rondell P.

Mayo Clinic

American Journal of Clinical Pathology | July 30, 2024 | Volume: 163 | Issue: 1 | Pages: 60-68

10.1093/ajcp/aqae094 | PMID 39078096 Get It

Abstract Objectives To describe mismatch repair (MMR) and microsatellite instability (MSI) testing practices in laboratories using the College of American Pathologists (CAP) MSI/MMR proficiency testing programs prior to the 2022 publication of the MSI/MMR practice guidelines copublished by CAP and the Association of Molecular Pathology (AMP). Methods Data from supplemental questionnaires provided with the 2020-B MSI/MMR programs to 542 laboratories across different practice settings were reviewed. Questionnaires contained 21 questions regarding the type of testing performed, specimen/tumor types used for testing, and clinical practices for checkpoint blockade therapy. Results Domestic laboratories test for MSI/MMR more often than international laboratories (P = .04) and academic hospitals/medical centers test more frequently than nonhospital sites/clinics (P = .03). The most commonly used testing modality is immunohistochemistry, followed by polymerase chain reaction, then next-generation sequencing. Most laboratories (72.6%; 347/478) reported awareness of the use of immune checkpoint inhibitor therapy for patients with high MSI or MMR-deficient results. Conclusions The results demonstrate the state of MMR and MSI testing in laboratories prior to the publication of the CAP/AMP best practice guidelines, highlighting differences between various laboratory types. The findings indicate the importance of consensus guidelines and provide a baseline for comparison after their implementation.
Incidence of Nonsynostotic Plagiocephaly and Developmental Disorders
Lynch, Mary E. , Rabatin, Amy E. , Brandenburg, Joline E. , Theuer, Amanda, Viet, Katrina M., Driscoll, Sherilyn W. , White, Melanie J, Theuer, Amanda B, White, Melanie J., Hollman, John H.

Mayo Clinic

JAMA Pediatrics | July 22, 2024 | Volume: 178 | Issue: 9 | Pages: 899

10.1001/jamapediatrics.2024.2304 | PMID 39037805 Get It

ImportanceThis is the first population-based study quantifying the incidence of nonsynostotic positional plagiocephaly and/or brachycephaly (PPB) in infancy and its association with developmental disorders.ObjectiveTo report the incidence of PPB before age 1 year, the incidence of craniosynostosis, and the percentage of children with PPB diagnosed with a developmental disorder by age 7 years.Design, Setting, and ParticipantsThis was a retrospective, population-based cohort study of children in the Rochester Epidemiology Project (REP) born in Olmsted County, Minnesota, from January 1, 2008, through December 31, 2012, with follow-up through age 7 years. Data were analyzed from March 2021 to April 2024.ExposurePhysical examination detecting cranial deformity.Main Outcomes and MeasuresThe primary outcome was the incidence of PPB. Secondary outcomes were the incidence of craniosynostosis and the percentage of children with PPB diagnosed with a developmental disorder by age 7 years.ResultsOf 9909 infants (5084 [51.3%] male; 9205 [92.9%] born at term and 704 [7.1%] born preterm) included in the study, 575 had PPB, for a PPB incidence of 5.8% (95% CI, 5.3%-6.3%). The incidence of PPB was 5.3% (95% CI, 4.8%-5.8%) in term infants vs 11.8% (95% CI, 9.4%-14.6%) in preterm infants. The incidence of craniosynostosis was 0.16% (95% CI, 0.09%-0.26%). A developmental disorder was known or suspected in 4.2% (95% CI, 2.7%-6.2%) of infants at the time of PPB diagnosis; among 402 infants with PPB and follow-up through age 7 years, 30 (7.5%; 95% CI, 5.0%-10.7%) had a confirmed developmental disorder by 7 years of age. The prevalence of autism spectrum disorder (ASD) in children with a history of PPB who were followed up to age 7 years was 2.2% (9 of 402 children).Conclusions and RelevanceThis study found that only a small percentage of the infants had positional head deformity significant enough to be documented and/or referred for subspecialty evaluation, and only a small subset of these children went on to have a developmental disorder in childhood. This information is helpful for counseling families about their child’s developmental risk at time of PPB diagnosis.
Association Between Surgeon Sex and Days Alive at Home Following Surgery: A Population-Based Cohort Study
Heybati, Kiyan , Satkunasivam, Raj , Aminoltejari, Khatereh, Thomas, Hannah S. , Salles, Arghavan , Coburn, Natalie, Wright, Frances C. , Conn, Lesley Gotlib , Riveros, Carlos , McCartney, Colin J. L. , Armstrong, Kathleen , Bass, Barbara L. , Detsky, Allan S. , Coburn, Natalie, Luckenbaugh, Amy N. , Ranganathan, Sanjana , Jerath, Angela , Wallis, Christopher J D

Mayo Clinic

Annals of Surgery Open | July 19, 2024 | Volume: 5 | Issue: 3 | Pages: e477

10.1097/as9.0000000000000477 | PMID 39310349 Get It

Objective: The objective of this study was to measure potential associations between surgeon sex and number of days alive and at home (DAH). Background: Patients treated by female surgeons appear to have lower rates of mortality, complications, readmissions, and healthcare costs when compared with male surgeons. DAH is a validated measure, shown to better capture the patient experience of postoperative recovery. Methods: We conducted a retrospective study of adults (≥18 years of age) undergoing common surgeries between January 01, 2007 and December 31, 2019 in Ontario, Canada. The outcome measures were the number of DAH within 30-, 90-, and 365-days. The data was summarized using descriptive statistics and adjusted using multivariable generalized estimating equations. Results: During the study period, 1,165,711 individuals were included, of which 61.9% (N = 721,575) were female. Those managed by a female surgeon experienced a higher mean number of DAH when compared with male surgeons at 365 days (351.7 vs. 342.1 days; P < 0.001) and at each earlier time point. This remained consistent following adjustment for covariates, with patients of female surgeons experiencing a higher number of DAH at all time points, including at 365 days (343.2 [339.5–347.1] vs. 339.4 [335.9–343.0] days). Multivariable regression modeling revealed that patients of male surgeons had a significantly lower number of DAH versus female surgeons. Conclusions: Patients of female surgeons experienced a higher number of DAH when compared with those treated by male surgeons at all time points. More time spent at home after surgery may in turn lower costs of care, resource utilization, and potentially improve quality of life. Further studies are needed to examine these findings across other care contexts.